Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments
Protocol outlines options for second-line soft tissue sarcoma treatments
This is a protocol for a systematic review and network meta-analysis. It will evaluate second-line pharmacological regimens for advanced sof…
A new protocol maps second-line drug choices for advanced soft tissue sarcoma patients previously treated with anthracyclines, noting curren…
Narrative review on anthracycline cardiorenal toxicity and dexrazoxane protection
Doctors seek better ways to protect heart and kidney health during cancer drug treatment
This narrative review synthesizes evidence on anthracycline-induced cardiorenal toxicity and dexrazoxane's protective role. The authors note…
Cancer treatments called anthracyclines can harm the heart and kidneys. This review explains why doctors need new strategies to keep patient…
Meta-analysis finds beta-blockers may reduce cardiotoxicity risk during cancer therapy
Heart-Protecting Meds Show Promise for Cancer Patients
A meta-analysis of 19 RCTs in patients receiving anthracyclines and/or trastuzumab found beta-blockers improved LVEF (WMD=2.19) and reduced…
Two specific heart medications stand out as the most effective shields against heart damage caused by powerful cancer treatments.
Atezolizumab plus chemotherapy improved progression-free survival and patient-reported quality of life in metastatic triple-negative breast cancer
Adding atezolizumab to chemotherapy improved quality of life and survival in some patients with metastatic triple-negative breast cancer
This randomized trial evaluated adding atezolizumab to anthracycline-based chemotherapy versus chemotherapy plus placebo in patients with me…
Adding atezolizumab to chemotherapy improved quality of life, emotional functioning, and pain for patients with metastatic triple-negative b…